Nowakowski, Grzegorz S.

AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 434

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey

Waterhouse, D. M., Harvey, R. D., Hurley, P., Levit, L. A., Kim, E. S., Klepin, H. D., Mileham, K. F., Nowakowski, G., Schenkel, C., Davis, C., et al. (2020) · JCO Oncology Practice

COVID-19 and healthcare impactsEducation during COVID-19 pandemic

Cited by 199

Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells

Shenoy, N., Bhagat, T., Nieves, E., Stenson, M., Lawson, J., Choudhary, G. S., Habermann, T., Nowakowski, G., Singh, R., Wu, X., et al. (2017) · Blood Cancer Journal

Epigenetics and DNA MethylationVitamin C and Antioxidants Research

Cited by 111

ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma

Vitolo, U., Witzig, T. E., Gascoyne, R. D., Scott, D. W., Zhang, Q., Jurczak, W., Özcan, M., Hong, X., Zhu, J., Jin, J., et al. (2019) · Hematological Oncology

Lymphoma Diagnosis and TreatmentViral-associated cancers and disorders

Cited by 84

Completed induction phase analysis of MAGNIFY: phase 3b study of lenalidomide + rituximab (R 2) followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma

Lansigan, F., Andorsky, D. J., Coleman, M., Yacoub, A., Melear, J., Fanning, S., Kolibaba, K. S., Reynolds, C. M., Nowakowski, G. S., Gharibo, M., et al. (2021) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 14